Ultragenyx Pharmaceutical | RARE - Cash And Equivalent


Ultragenyx Pharmaceutical reported $175M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Immunic USD 186.63M 171.15M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Kyowa Hakko Kirin JPY 218.77B 15.83B Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
Moderna USD 1.91B 687M Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xoma USD 143.9M 7.68M Jun/2024